To compare the clinical efficacy of two commercially available valved holding chambers (VHCs) for salbutamol treatment in young children with acute wheezing, addressing a significant gap in pediatric care.
Key Findings:
In vitro studies indicated up to 23-fold differences in drug delivery between VHCs.
VHC-1 demonstrated higher drug delivery performance compared to VHC-2, leading to improved clinical outcomes.
Clinical outcomes and response to treatment were evaluated 20 minutes post-administration, focusing on respiratory distress scores.
Interpretation:
The study aims to provide evidence on the clinical impact of different VHCs in pediatric acute care, highlighting the need for optimized inhalation therapy practices.
Limitations:
Enrollment was interrupted due to COVID-19 restrictions, potentially affecting sample size and generalizability.
The study design did not blind nurses and guardians, which may introduce bias in treatment administration and affect the perceived efficacy.
Conclusion:
This study seeks to clarify the efficacy of different VHCs in treating acute wheezing in young children, contributing valuable data to pediatric inhalation therapy practices and addressing a critical gap in the literature.
by Péter Csonka, Terhi Ruuska-Loewald, Inka Hämynen, Minna Honkila, Iida Ojaniemi, Eeva Mykkänen, Balázs Kelemen, Minna Juntunen, Salla Kuusela, Marjo Renko, Lauri Lehtimäki, Tytti Pokka, Sauli Palmu
